Ophthalmology
Volume 118, Issue 3 , Pages 459-467 , March 2011

Randomized Evaluation of the Trabecular Micro-Bypass Stent with Phacoemulsification in Patients with Glaucoma and Cataract

Presented at: the American Academy of Ophthalmology 2009 Annual meeting, October 2009, San Francisco, California; and in part at the American Society of Cataract and Refractive Surgery 2010 Annual Meeting, April 2010, Boston, Massachusetts.

  • Thomas W. Samuelson, MD

      Affiliations

    • Minnesota Eye Consultants, Minneapolis, Minnesota
    • ,
  • L. Jay Katz, MD

      Affiliations

    • Wills Eye Hospital, Philadelphia, Pennsylvania
    • ,
  • Jeffrey M. Wells, PharmD

      Affiliations

    • Glaukos Corporation, Laguna Hills, California
    • ,
  • Yi-Jing Duh, PhD

      Affiliations

    • ClinReg Consulting, Inc., Laguna Beach, California
    • ,
  • Jane Ellen Giamporcaro, BS

      Affiliations

    • Glaukos Corporation, Laguna Hills, California
    • Corresponding Author InformationCorrespondence: Jane Ellen Giamporcaro, BS, Glaukos Corp., 26051 Merit Circle #103, Laguna Hills, CA 92653
    • ,
  • US iStent Study Group

Received 19 December 2009 ,Revised 1 July 2010 ,Accepted 7 July 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Manuscript no. 2009-1734.

 Financial Disclosure(s): The author(s) have made the following disclosure(s): TWS: C, O to Glaukos, and C to Alcon, Allergan, AMO, AqueSys, iScience, Ivantis, Pfizer, QLT, and Santen. LJK: C, O to Glaukos, C to Allergan, Alcon, Pfizer, and Lumenis; JW: E, O to Glaukos; Y-JD: C, O to Glaukos and C to Ivantis; JEG: E, O to Glaukos. All the investigators were consultants to Glaukos for the conduct of this study. In addition, Drs. Bacharach, Buznego, Cantor, and Nichamin are equity owners of Glaukos.

 Funding: Glaukos Corp.

 This study was registered with clinicaltrials.gov as NCT00323284.

PII: S0161-6420(10)00743-8

doi: 10.1016/j.ophtha.2010.07.007

Ophthalmology
Volume 118, Issue 3 , Pages 459-467 , March 2011

Article Tools

* Image Usage & Resolution